We strive to discover and develop truly effective therapeutics for neurodegenerative diseases.
We are a passionate team of scientists and drug developers dedicated to improving the lives of patients affected by neurodegenerative diseases.
Our R&D pipeline
Our pipeline of innovative small molecules has the potential to halt and prevent neurodegeneration in certain brain diseases.
Asceneuron discovers and develops groundbreaking therapeutics for neurodegenerative disorders with high unmet medical needs:
orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
News & Events
- - NewsRead a detailed conference report on our clinical tau modifier presented at AD/PD 2017
- - Press releasesAsceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor
First-in-human trial of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles to fight neurodegenerative diseases including dementia
- - EventAsceneuron to participate in the 1st EuroTauMeeting or how to know everything about Tau protein and associated diseases in Lille, France, on April 27-28, 2017.
- - EventAsceneuron to present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases on 29 March 2017 in Vienna, Austria.
- - Press releasesAsceneuron today announced the appointment of J. Michael Ryan, M.D. as Chief Medical Officer. With over 15 years of Central Nervous System (CNS) clinical research experience, Michael brings extensive drug development expertise to Asceneuron. He will be responsible for advancing Asceneuron’s pipeline of innovative small molecules and progressing tau modifiers through the clinic.
- - EventAsceneuron to attend the 35th Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2017 at the Westin St. Francis in San Francisco, CA.
- - EventAsceneuron will present a poster on the M1 PAM program at the Society for Neuroscience (SfN) Annual Meeting 2016 on November 12-16, 2016 in San Diego, USA.
- - Press releasesAsceneuron has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research for the further development of positive allosteric modulators of the M1 muscarinic acetylcholine receptor.
- - EventAsceneuron to attend Bio-Europe partnering event on 7-9 November, 2016 in Cologne, Germany